Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Rep. Pitts To Offer Amendment Excluding Abortion Coverage From House Health Care Bill
Rep. Joe Pitts (R-Pa.) said he plans to introduce an amendment to the House health care overhaul bill (HR 3200) that would prohibit insurers from being required to cover abortion, unless the woman"s life is at risk or the pregnancy is a result of rape or incest, CQ Today reports. Pitts said he will offer the amendment Thursday at the first House Energy and Commerce Committee mark-up session.The House bill would authorize the Obama administration to craft minimum benefit standards for health insurance plans, CQ Today reports. President Obama has said that he considers reproductive health care an essential service. Democrats say Republicans are trying to expand the Hyde amendment"s exclusion on using federal Medicaid funding to cover abortion to all health care services. Rep. Diana DeGette (D-Colo.), vice chair of the Energy and Commerce Committee, said, "I think that if anti-choice Republicans or others see this as an opportunity to expand prohibitions on a legally allowed and medically appropriate practice, then they are wrong." She added, "We are not going to use the health care bill to expand prohibitions on a legal medical practice, period." Pitts, Rep. Christopher Smith (R-N.J.) and other supporters of the amendment say it is necessary to block the administration from requiring abortion coverage. The committee has blocked three of Smith"s abortion-related amendments so far this year (Wayne, CQ Today, 7/15).
generic viagra online
Are Angiotensins Involved In The Hemodynamic Changes Of Cirrhosis Patients?
Liver cirrhosis has been recently studied in the light of the new view of the renin angiotensin system (RAS). While the angiotensin converting enzyme (ACE)-Ang 2-AT1 receptor arm contributes to liver tissue injury and fibrosis and the maintenance of basal vascular tonus in non-compensated cirrhosis, the activation of the ACE2-Ang-(1-7)-Mas receptor arm exerts anti-fibrotic actions and probably has also a role in arterial vasodilation in liver cirrhosis. In a previous study published last year in WJG by the same research group, it was shown that chronic treatment with propranolol in cirrhotic patients was characterized by marked changes in the precursors of the RAS cascade (renin and Ang 1 with repercussions on the 2 main RAS components, Ang 2 and Ang-(1-7), in the splanchnic and peripheral circulation. Therefore, the circulating profile of RAS components at different stages of liver cirrhosis and their role in hemodynamic changes of cirrhosis remained unclear.
News of the day
Siemens Enterprise Communications To Provide Multi-million Pound Secure LAN For Barts And The London NHS Trust Hospitals
Siemens Enterprise Communications has won a four year multi-million pound framework contract to provide Barts and The London NHS Trust with an integrated Enterasys fixed and wireless LAN and security infrastructure. The first phase in a three stage communications programme, the new infrastructure - due for completion in 2010 - will provide a single network able to handle all optical images, video streaming and traffic from multiple wireless devices and PCs for 300 beds at Barts hospital.
Public Health

Agios Pharmaceuticals' Focus Of Drug Research - Cancer Metabolism - Selected For Stand Up To Cancer Grant

Agios Pharmaceuticals today announced that Stand Up To Cancer (SU2C), a charitable initiative for new cancer treatments, has selected the Cancer Metabolism "dream team" led by Agios founder Dr. Craig Thompson and including Agios advisors Drs. Chi Dang and Joshua Rabinowitz. Cancer Metabolism is one of only five research areas chosen to share in $73.6 million in translational research funding, based on a rigorous selection process by independent scientific advisors assembled by SU2C"s scientific partner, the American Association for Cancer Research (AACR). Cancer metabolism is a new and exciting field of biology that represents a breakthrough understanding of how cancer cells become addicted to using more nutrients than normal cells to ensure their survival and growth. This new understanding of a fundamental mechanism of cancer represents a powerful Achilles" heel to target this deadly disease. With the help of Craig Thompson, MD, Chi Dang, MD, and other key advisors including Lewis Cantley, PhD, and Tak Mak, PhD, Agios was founded a year ago to lead the translation of cancer metabolism biology and decades of metabolic biochemistry into novel cancer therapeutics that will make a difference for patients. In its first year of operation, Agios has taken a leadership position in the field of Cancer Metabolism with more than 40 employees and a rapidly emerging drug pipeline. Yesterday, Agios announced the appointment of its new leadership team to further lead and grow the vision of Agios. David Schenkein, MD, of Genentech will assume his role as Chief Executive Officer in August and Duncan Higgons, formerly of Archemix, became the Chief Operating Officer in May. "It is great to see Stand Up To Cancer and AACR recognize and further validate the therapeutic potential of Cancer Metabolism which has been the driving vision behind building Agios over the past year," said David Schenkein, incoming Chief Executive Officer of Agios Pharmaceuticals. "The progress to date of Agios has been impressive, bringing together great people, a passionate culture, deep science and an emerging pipeline of novel drugs that is leading the field rapidly downstream towards the clinic." Stand Up To Cancer worked in collaboration with the American Association for Cancer Research (AACR) to identify and fund "dream teams" in areas of cancer research that provide the most promising near term potential breakthrough therapies for patients. Cancer Metabolism was selected as one of the five research areas to receive SU2C research grants, based on the recommendation of a scientific advisory committee assembled by AACR. The Cancer Metabolism dream team includes four elite scientists, three of whom are key Agios founders and advisors: - Co-Leader - Agios Co-Founder Craig B. Thompson, M.D., Director, Abramson Cancer Center, University of Pennsylvania. - Principal Reseacher - Agios Advisor Chi Van Dang, M.D., Ph.D., Vice Dean for Research of Johns Hopkins University School of Medicine. - Principal Researcher - Agios Advisor Joshua D. Rabinowitz, M.D., Ph.D., Assistant Professor of Chemistry and Integrated Genomics, Princeton University. Agios Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009